Transfer of Distribution Rights for Antiparkinson's Disease Agent "CABASER® Tab. 0.25mg・1.0mg"

Kissei Pharmaceutical Co., Ltd [President and CEO: Mutsuo Kanzawa ("Kissei")] announced today that Kissei will transfer the rights to distribute the Antiparkinson's disease agent "CABASER^® Tab. 0.25mg・1.0mg" (generic name: cabergoline), which has been manufactured by Pfizer Japan Inc. [President and Representative Director: Ichiro Umeda ("Pfizer")] and distributed by Kissei, to Pfizer effective on April 1, 2012.
Kissei has launched this drug in August 1999, and the distribution rights are transferred based on the expiration of the contract as of March 31, 2012, which was agreed by both companies.

The impact from this event on Kissei's financial forecast on the current fiscal year (from April 1, 2011 to March 31, 2012) will be immaterial.